Germany: Raltegravir, Federal Court of Justice of Germany, X ZB 2/17, 11 July 2017
In this case the Federal Court of Justice (FCJ) allowed a compulsory licence under a patent for a pharmaceutical active ingredient for the first time ever. The Court held that a public interest in such a licence may still exist where it concerns only a small group of patients. In particular, the interest may be…